Evaluation of Single-Dose Ilofotase Alfa in Adult Patients with Hypophosphatasia: A Pilot Study

The primary objective of this pilot trial is to evaluate the effects of a single dose of **ilofotase alfa** in patients with **hypophosphatasia**. Hypophosphatasia is a rare metabolic bone disease characterized by defective bone mineralization, leading to a range of clinical manifestations from mild to severe. Understanding the impact of ilofotase alfa on this condition is clinically relevant as it may offer insights into potential therapeutic benefits and inform future treatment strategies for affected individuals.

The clinical trial focuses on participants diagnosed with **Hypophosphatasia**, a rare metabolic bone disease. The study population includes both male and female subjects, with an age range encompassing children and adolescents. The trial does not specifically target a vulnerable population. The sponsor has not provided information regarding the total number of participants involved in the study. Selection criteria for the trial population, as well as any lifestyle considerations such as diet or physical activity, have not been disclosed. Key inclusion or exclusion criteria are also not specified in the available data.

The clinical trial is designed to evaluate the effects of a single dose of **ilofotase alfa** in patients diagnosed with **hypophosphatasia**. This study is a Phase 3 trial, which is typically conducted to confirm the efficacy and monitor the side effects of the treatment in a larger patient group. The trial follows a randomized, double-blind, controlled design to ensure the reliability and validity of the results. The estimated duration of the trial spans from April 15, 2023, to June 15, 2023, encompassing both the recruitment and treatment phases.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit. During this visit, eligibility criteria will be assessed to ensure that participants meet the necessary conditions for inclusion in the trial. Following the initial screening, participants will be randomly assigned to either the treatment group receiving ilofotase alfa or a control group. Subsequent follow-up visits will be scheduled to monitor the participants' response to the treatment and to collect data on any adverse effects. The end-of-study visit will mark the conclusion of the participant's involvement, during which final assessments will be conducted to evaluate the overall outcomes of the treatment.

The expected length of participant involvement in the trial is approximately two months, from the initial screening to the end-of-study visit. Participants may be subject to early termination from the study if they experience significant adverse effects, fail to comply with study protocols, or withdraw consent. The trial is conducted under strict ethical guidelines to ensure the safety and well-being of all participants throughout the study duration.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the **experimental medication**, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the absence of specific details, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be described. The data does not include any information about the **disease** being studied or the main objective of the trial. Consequently, a comprehensive description of the treatments used in this clinical trial cannot be constructed based on the current dataset.

The clinical trial is in Phase 3, with an estimated recruitment start date of April 15, 2023, and an estimated end date of June 15, 2023. Efficacy will be assessed through the evaluation of primary and secondary endpoints, although specific endpoints are not detailed in the provided data. The trial will follow a structured schedule for measuring and collecting efficacy parameters, adhering to the standards expected in Phase 3 trials. The methods for analysis will be consistent with those typically employed in clinical trials of this phase, ensuring robust and reliable results. The trial's design will focus on generating data that can support the efficacy claims of the investigational product, contributing to the overall understanding of its therapeutic potential.